Sara M Tolaney

Sara M Tolaney

UNVERIFIED PROFILE

Are you Sara M Tolaney?   Register this Author

Register author
Sara M Tolaney

Sara M Tolaney

Publications by authors named "Sara M Tolaney"

Are you Sara M Tolaney?   Register this Author

68Publications

2647Reads

32Profile Views

Reply to A.K. Goel et al.

J Clin Oncol 2019 Nov 13;37(31):2954-2955. Epub 2019 Sep 13.

Sara M. Tolaney, MD, MPH and Eric P. Winer, MD, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01822DOI Listing
November 2019

CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?

Lancet Oncol 2019 Nov 28;20(11):1479-1481. Epub 2019 Sep 28.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30627-8DOI Listing
November 2019

A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.

Breast Cancer Res Treat 2019 Sep 20. Epub 2019 Sep 20.

Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05445-zDOI Listing
September 2019

Utilization of tumor genomics in clinical practice: an international survey among ASCO members.

Future Oncol 2019 Jul 26;15(21):2463-2470. Epub 2019 Jun 26.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0010DOI Listing
July 2019

Evidence to date: talazoparib in the treatment of breast cancer.

Onco Targets Ther 2019 2;12:5177-5187. Epub 2019 Jul 2.

Breast Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S184971DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612288PMC
July 2019

How we treat locally advanced HER2-positive breast cancer.

Clin Adv Hematol Oncol 2019 May;17(5):271-280

Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
May 2019

HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance.

Ther Adv Med Oncol 2019 19;11:1758835919833519. Epub 2019 Mar 19.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1758835919833519
Publisher Site
http://dx.doi.org/10.1177/1758835919833519DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425535PMC
March 2019

Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Endocr Rev 2019 02;40(1):17-65

Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/er.2018-00006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6270990PMC
February 2019

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

N Engl J Med 2019 02;380(8):741-751

From the Massachusetts General Hospital Cancer Center (A.B., S.J.I.) and Dana-Farber Cancer Institute (S.M.T.), Harvard Medical School, Boston; Vanderbilt-Ingram Cancer Center, Nashville (I.A.M., V.G.A.); Weill Cornell Medical College (L.T.V.) and New York-Presbyterian-Columbia University Irving Medical Center (K.K.), New York; University of Colorado Cancer Center, Aurora (J.R.D.); Texas Oncology, Baylor University Medical Center, US Oncology, Dallas (J.O.); Orlando Health University of Florida Health Cancer Center, Orlando (R.L.M., N.C.S.); Yale University School of Medicine, New Haven, CT (A.D.S.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (H.S.R.); Immunomedics, Morris Plains, NJ (D.M.G., R.I., S.W., R.M.S., W.A.W.); and AIS Consulting, Ann Arbor, MI (A.M.S.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1814213
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1814213DOI Listing
February 2019

Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?

Stem Cell Investig 2019 22;6. Epub 2019 Feb 22.

Breast Oncology Program and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://sci.amegroups.com/article/view/24095/html
Publisher Site
http://dx.doi.org/10.21037/sci.2019.02.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414355PMC
February 2019

Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the gene polymorphism.

J Med Genet 2019 Jan 4;56(1):39-42. Epub 2018 Oct 4.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://jmg.bmj.com/lookup/doi/10.1136/jmedgenet-2018-105485
Publisher Site
http://dx.doi.org/10.1136/jmedgenet-2018-105485DOI Listing
January 2019

Optimal treatment of early stage HER2-positive breast cancer.

Cancer 2018 12 6;124(23):4455-4466. Epub 2018 Oct 6.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31657DOI Listing
December 2018

Database Selection and Heterogeneity-More Details, More Credibility-Reply.

JAMA Oncol 2018 09;4(9):1295-1296

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.1231DOI Listing
September 2018

Occurrence and significance of morphologic changes in patients with metastatic triple negative breast cancer treated with Cabozantinib.

Clin Imaging 2018 Mar - Apr;48:44-47. Epub 2017 Sep 28.

Department of Imaging, Dana-Farber Cancer Institute, Boston, USA; Department of Radiology, Brigham and Women's Hospital, Boston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinimag.2017.09.014DOI Listing
August 2018

CDK4/6 inhibition in breast cancer: current practice and future directions.

Ther Adv Med Oncol 2018 17;10:1758835918786451. Epub 2018 Jul 17.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835918786451DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050811PMC
July 2018

De-escalating treatment in the adjuvant setting in HER2-positive breast cancer.

Future Oncol 2018 Apr 28;14(10):937-945. Epub 2018 Mar 28.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-2500DOI Listing
April 2018

Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.

Cancer 2018 03 3;124(6):1111-1121. Epub 2018 Jan 3.

Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31200
Publisher Site
http://dx.doi.org/10.1002/cncr.31200DOI Listing
March 2018

Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.

Breast Cancer Res Treat 2018 02 4;167(3):607-614. Epub 2017 Nov 4.

Breast Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-017-4560-6
Publisher Site
http://dx.doi.org/10.1007/s10549-017-4560-6DOI Listing
February 2018

Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.

J Clin Oncol 2018 02 3;36(6):543-553. Epub 2018 Jan 3.

Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus, OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E. Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin, Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston; Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed, Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of Technology; and J. Christopher Love, Massachusetts Institute of Technology, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.0033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815405PMC
February 2018

Optimal Management of Early and Advanced HER2 Breast Cancer.

Am Soc Clin Oncol Educ Book 2017 ;37:76-92

From the David Geffen School of Medicine, University of California, Los Angeles, CA; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_175630DOI Listing
December 2017

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

J Clin Oncol 2017 Jul 14;35(19):2141-2148. Epub 2017 Mar 14.

Aditya Bardia, Steven J. Isakoff, and Dejan Juric, Massachusetts General Hospital Cancer Center; Aditya Bardia, Steven J. Isakoff, Dejan Juric, and Sara M. Tolaney, Harvard Medical School; Sara M. Tolaney, Dana-Farber Cancer Institute, Boston, MA; Ingrid A. Mayer, Vandana Abramson, and Jordan Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN; Jennifer R. Diamond and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Rebecca L. Moroose and Nikita C. Shah, University of Florida Health Cancer Center, Orlando, FL; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Joyce O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center; Joyce O'Shaughnessy, US Oncology, Dallas, TX; Kevin Kalinsky, Columbia University Herbert Irving Comprehensive Cancer Center; Allyson J. Ocean and Linda T. Vahdat, Weill Cornell Medicine, New York, NY; Michael Guarino, Helen F. Graham Cancer Center, Newark, DE; William A. Wegener, Pius Maliakal, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.8297DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559902PMC
July 2017

A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.

Invest New Drugs 2017 02 16;35(1):68-78. Epub 2016 Nov 16.

University of California - San Francisco, Box 1705, UCSF, San Francisco, CA, 94143-1705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-016-0399-7DOI Listing
February 2017

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.

Breast Cancer Res Treat 2016 11 6;160(2):305-312. Epub 2016 Oct 6.

Department of Medical Oncology, Breast Oncology Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-4001-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065609PMC
November 2016

The evolving understanding of small HER2-positive breast cancers: matching management to outcomes.

Future Oncol 2015 13;11(24):3261-71. Epub 2015 Nov 13.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon.15.240
Publisher Site
http://dx.doi.org/10.2217/fon.15.240DOI Listing
September 2016

Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.

Breast Care (Basel) 2016 Jun 22;11(3):167-73. Epub 2016 Jun 22.

Breast Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA, MA, USA; Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000447284DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960359PMC
June 2016

Randomized trial of a physical activity intervention in women with metastatic breast cancer.

Cancer 2016 Apr 12;122(8):1169-77. Epub 2016 Feb 12.

Breast Oncology Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29899DOI Listing
April 2016

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.

Cancer Cell 2016 Mar;29(3):255-269

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.02.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794996PMC
March 2016

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

J Clin Oncol 2015 Jan 4;33(1):13-21. Epub 2014 Aug 4.

William M. Sikov, Miriam Hospital and Alpert Medical School of Brown University, Providence, RI; Donald A. Berry, University of Texas MD Anderson Cancer Center, Houston, TX; Charles M. Perou and Lisa A. Carey, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill; Constance T. Cirrincione, Alliance Statistical Center, Durham; Charles S. Kuzma, Southeast Cancer Control Consortium, Winston-Salem, NC; Baljit Singh, New York University Medical Center; Elisa R. Port, Mount Sinai Medical Center; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Sara M. Tolaney, Mehra Golshan, Jennifer R. Bellon, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Timothy J. Pluard, Washington University-St Louis Medical Center, St Louis, MO; George Somlo, City of Hope Comprehensive Cancer Center, Duarte; Deborah Collyar, Patient Advocates in Research, Danville, CA; and Olwen M. Hahn, University of Chicago Medical Center, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.0572DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268249PMC
January 2015

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

N Engl J Med 2015 Jan;372(2):134-41

From the Departments of Medical Oncology (S.M.T., B.A.O., A.H.P., I.E.K., H.J.B., E.P.W.) and Biostatistics and Computation Biology (W.T.B., H.G.), Dana-Farber Cancer Institute, and Department of Hematology-Oncology, Massachusetts General Hospital (B.M.) - both in Boston; Breast Cancer Medicine Service, Department of Medicine, Solid Tumor Division, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Cornell Medical Center, New York (C.T.D., C.A.H.), and Department of Medical Oncology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park (I.S.) - all in New York; Sarah Cannon Cancer Center, Department of Medical Oncology, Nashville (D.A.Y.); Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham (P.K.M.), and Department of Medical Oncology, University of North Carolina, Chapel Hill (L.A.C.) - both in North Carolina; Cardinal Bernardin Cancer Center, Department of Medicine, Division of Hematology-Oncology, Loyola University Chicago Stritch School of Medicine, Maywood, IL (K.S.A.); Comprehensive Cancer Center, Department of Medicine, Division of Oncology, University of California, San Francisco, San Francisco (H.S.R.); Department of Medical Oncology, Washington University in St. Louis, St. Louis (M.E.); and Johns Hopkins Kimmel Cancer Center, Department of Oncology, Baltimore (A.C.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1406281DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313867PMC
January 2015

Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance).

J Clin Oncol 2014 Dec 27;32(35):3959-66. Epub 2014 Oct 27.

Harold J. Burstein, William T. Barry, Sara M. Tolaney, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Constance T. Cirrincione, Duke University Alliance Statistics and Data Center; Kimberly L. Blackwell, Duke University Medical Center, Durham, NC; Helen K. Chew, University of California, Davis, Davis, CA; Diana E. Lake and Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; and Cynthia Ma, Washington University School of Medicine, St Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.7941DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251959PMC
December 2014

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

J Clin Oncol 2014 Jan 9;32(2):68-75. Epub 2013 Dec 9.

Leena Gandhi, Sara M. Tolaney, James M. Cleary, and Geoffrey I. Shapiro, Dana-Farber Cancer Institute; Eunice L. Kwak, Massachusetts General Hospital; Shuchi S. Pandya, Beth Israel Deaconess Medical Center, Boston; Anna Berkenblit and Mizue Krygowski, Aveo Pharmaceuticals; Revathi Ananthakrishnan and Kathleen W. Turnbull, Inventiv Health, Cambridge, MA; Rastislav Bahleda, Antoine Hollebecque, and Jean-Charles Soria, Insitut Gussav Roussy, Villejuif, France; Richat Abbas and Yali Liang, Pfizer, Collegeville, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2012.47.2787
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.47.2787DOI Listing
January 2014

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.

Breast Cancer Res Treat 2013 Oct 24;141(3):421-7. Epub 2013 Sep 24.

Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-013-2700-1DOI Listing
October 2013

Mechanisms of trastuzumab resistance in breast cancer.

Anticancer Agents Med Chem 2009 Mar;9(3):348-55

Dana Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871520610909030348DOI Listing
March 2009

Lymphopenia associated with adjuvant anthracycline/ taxane regimens.

Clin Breast Cancer 2008 Aug;8(4):352-6

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2008.n.041DOI Listing
August 2008

Follow-up care of patients with breast cancer.

Breast 2007 Dec 13;16 Suppl 2:S45-50. Epub 2007 Aug 13.

Dana Farber Cancer Institute, 44 Binney Street, Mayer 2, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2007.07.005DOI Listing
December 2007

Sarcoidosis mimicking metastatic breast cancer.

Clin Breast Cancer 2007 Oct;7(10):804-10

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2007.n.044DOI Listing
October 2007

Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer.

J Clin Oncol 2006 Nov;24(33):5330-1

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.08.1083DOI Listing
November 2006